Article
Mutation position is an important determinant for predicting cancer neoantigens.
The Journal of experimental medicine - 6 Apr 2020
Capietto Aude-Hélène, Jhunjhunwala Suchit, Pollock Samuel B, Lupardus Patrick, Wong Jim, Hänsch Lena, Cevallos James, Chestnut Yajun, Fernandez Ajay, Lounsbury Nicolas, Nozawa Tamaki, Singh Manmeet, Fan Zhiyuan, de la Cruz Cecile C, Phung Qui T, Taraborrelli Lucia, Haley Benjamin, Lill Jennie R, Mellman Ira, Bourgon Richard, Delamarre Lélia
Abstract excerpt
Tumor-specific mutations can generate neoantigens that drive CD8 T cell responses against cancer. Next-generation sequencing and computational methods have been successfully applied to identify mutations and predict neoantigens. However, only a small fraction of predicted neoantigens are immunogenic. Currently, predicted peptide binding affinity for MHC-I is often the major criterion for prioritizing neoantigens,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.